Ignite Creation Date:
2024-06-16 @ 11:48 AM
Last Modification Date:
2024-10-26 @ 3:31 PM
Study NCT ID:
NCT06438055
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-05-31
First Post:
2024-05-26
Brief Title:
Clinical Treatment of Refractory Breast Cancer Based on Organoid Drug Sensitivity Results
Sponsor:
Tianjin Medical University Cancer Institute and Hospital
Organization:
Tianjin Medical University Cancer Institute and Hospital
Study Overview
Official Title:
Clinical Treatment of Refractory Breast Cancer Based on Organoid Drug Sensitivity Results
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study aims to enroll refractory breast cancer patients Patient-derived organoid will be established and drug sensitivity test will be conducted to intervene in the selection of clinical treatment plans Efficacy evaluation and prognosis analysis will also be conducted It is hoped that this study will provide a basis for the development of personalized treatment plans
Detailed Description:
Forty patients with refractory breast cancer who met the inclusion criteria were enrolled in the study after signing an informed consent form Tumor samples were obtained through clinical puncture and qualified samples were subjected to organoid modeling Perform drug sensitivity test on the established breast cancer organoids The drugs used are all that have been marketed and applied in clinical practice According to the results of organoid drug sensitivity analysis the patient received a treatment plan with relatively sensitive drugs Follow up prognostic data and relevant clinical information of enrolled patients conduct statistical analysis on the consistency between drug sensitivity test results and patient treatment response and evaluate the clinical effectiveness of treatment plans guided by organoid drug sensitivity results
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None